PMID- 22723081
OWN - NLM
STAT- MEDLINE
DCOM- 20121220
LR  - 20151119
IS  - 1573-7233 (Electronic)
IS  - 0167-7659 (Linking)
VI  - 31 Suppl 1
DP  - 2012 Sep
TI  - The role of pharmacogenomics in metastatic renal cell carcinoma.
PG  - S29-32
LID - 10.1007/s10555-012-9356-x [doi]
AB  - Pharmacogenomics is the study of how variation in the genetic background affects 
      an individual's response to a specific drug and/or its metabolism. Using 
      knowledge about the genes which produce the enzymes that metabolize a specific 
      drug, a physician may decide to raise or lower the dose, or even change to a 
      different drug. Targeted therapy with tyrosine kinase inhibitors (TKIs) and 
      mammalian target of rapamycin (mTOR) inhibitors has led to a substantial 
      improvement in the standard of care for patients with advanced or metastatic 
      renal cell carcinoma (RCC). Although few studies have identified biomarkers that 
      predict the response of targeted drugs in the treatment of metastatic RCC, some 
      associations have been found. Several studies have identified genetic 
      polymorphisms with implications in the pharmacokinetics and/or pharmacodynamics 
      of TKIs and mTOR inhibitors and which are associated with a prolonged 
      progression-free survival and/or overall survival in patients with metastatic 
      RCC. Among the genes of interest, we should consider IL8, FGFR2, VEGFA, FLT4, and 
      NR1I2. In this review, we discuss single nucleotide polymorphisms (SNPs) 
      associated with outcome and toxicity following targeted therapies and provide 
      recommendations for future trials to facilitate the use of SNPs in personalized 
      therapy for this disease.
FAU - Castellano, Daniel
AU  - Castellano D
AD  - Hospital Universitario 12 de Octubre, Madrid, Spain.
FAU - Virizuela, Juan Antonio
AU  - Virizuela JA
FAU - Cruz, Josefina
AU  - Cruz J
FAU - Sepulveda, Juan Manuel
AU  - Sepulveda JM
FAU - Saez, Maria Isabel
AU  - Saez MI
FAU - Paz-Ares, Luis
AU  - Paz-Ares L
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cancer Metastasis Rev
JT  - Cancer metastasis reviews
JID - 8605731
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
EIN - Cancer Metastasis Rev. 2013 Jun;32(1-2):317. Saenz, Maribel [corrected to Saez, 
      Maria Isabel]
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Renal Cell/*drug therapy/*genetics/metabolism/pathology
MH  - Drug Delivery Systems
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/*genetics/metabolism/pathology
MH  - Neoplasm Metastasis
MH  - Pharmacogenetics
MH  - Polymorphism, Single Nucleotide
MH  - Protein Kinase Inhibitors/*therapeutic use
EDAT- 2012/06/23 06:00
MHDA- 2012/12/21 06:00
CRDT- 2012/06/23 06:00
PHST- 2012/06/23 06:00 [entrez]
PHST- 2012/06/23 06:00 [pubmed]
PHST- 2012/12/21 06:00 [medline]
AID - 10.1007/s10555-012-9356-x [doi]
PST - ppublish
SO  - Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S29-32. doi: 
      10.1007/s10555-012-9356-x.